Cargando…
The epigenetic factor BORIS (CTCFL) controls the androgen receptor regulatory network in ovarian cancer
The identification of prognostic biomarkers is a priority for patients suffering from high-grade serous ovarian cancer (SOC), which accounts for >70% of ovarian cancer (OC) deaths. Meanwhile, borderline ovarian cancer (BOC) is a low malignancy tumor and usually patients undergo surgery with low p...
Autores principales: | Salgado-Albarrán, Marisol, González-Barrios, Rodrigo, Guerra-Calderas, Lissania, Alcaraz, Nicolás, Estefanía Sánchez-Correa, Thalía, Castro-Hernández, Clementina, Sánchez-Pérez, Yesennia, Aréchaga-Ocampo, Elena, García-Carrancá, Alejandro, Cantú de León, David, Herrera, Luis A., Baumbach, Jan, Soto-Reyes, Ernesto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690894/ https://www.ncbi.nlm.nih.gov/pubmed/31406110 http://dx.doi.org/10.1038/s41389-019-0150-2 |
Ejemplares similares
-
Epigenetic deregulation of BORIS and CTCF in breast cancer
por: Alcalá Moreno, Iliana, et al.
Publicado: (2013) -
CTCFL regulates the PI3K-Akt pathway and it is a target for personalized ovarian cancer therapy
por: Salgado-Albarrán, Marisol, et al.
Publicado: (2022) -
CTCF-KDM4A complex correlates with histone modifications that negatively regulate CHD5 gene expression in cancer cell lines
por: Guerra-Calderas, Lissania, et al.
Publicado: (2018) -
The Evolution of Epigenetic Regulators CTCF and BORIS/CTCFL in Amniotes
por: Hore, Timothy A., et al.
Publicado: (2008) -
Widespread Expression of BORIS/CTCFL in Normal and Cancer Cells
por: Jones, Tania A., et al.
Publicado: (2011)